Experimental tumor injection trial halted early

NCT ID NCT03871348

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-stage trial tested an experimental drug called SAR441000, injected directly into tumors, either alone or with another drug (cemiplimab) given through a vein. The study aimed to find a safe dose and see if the combination could shrink tumors in people with advanced solid cancers like melanoma. However, the trial was terminated early, so full results are not available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAR441000 (injected into tumors) and cemiplimab (given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early (Phase 1) trial that was terminated, so results are limited. The approach is experimental and may not prove safe or effective.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck squamous cell carcinoma lymphoma metastatic melanoma metastatic neoplasm neoplasm Neoplasm Metastasis skin squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC NEOPLASM

Contacts and locations

Locations

Cleveland Clinic - Cleveland- Site Number : 8400007

Cleveland, Ohio, 44195, United States
Dana-Farber Cancer Institute- Site Number : 8400003

Boston, Massachusetts, 02215, United States
Investigational Site Number : 0560001

Brussels, 1200, Belgium
Investigational Site Number : 0560002

Leuven, 3000, Belgium
Investigational Site Number : 0560003

Ghent, 9000, Belgium
Investigational Site Number : 2500001

Villejuif, 94805, France
Investigational Site Number : 2500002

Paris, 75010, France
Investigational Site Number : 2500004

Marseille, 13885, France
Investigational Site Number : 2760001

Mainz, 55131, Germany
Investigational Site Number : 2760003

Mannheim, 68167, Germany
Investigational Site Number : 2760004

Heidelberg, 69120, Germany
Investigational Site Number : 2760005

Hamburg, 20246, Germany
Investigational Site Number : 2760006

Tübingen, 72076, Germany
Investigational Site Number : 5280001

Rotterdam, 3015 CE, Netherlands
Investigational Site Number : 5280002

Nijmegen, 6525 GA, Netherlands
Investigational Site Number : 7240001

Pamplona, Navarre, 31008, Spain
Investigational Site Number : 7240002

Valencia, 46014, Spain
Investigational Site Number : 7240004

Barcelona, Catalunya [Cataluña], 08036, Spain
The University of Texas MD Anderson Cancer Center- Site Number : 8400002

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.